• Autoantibodies;
  • autoantigens;
  • cholestatic;
  • epitopes;
  • liver autoimmunity


  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

Primary biliary cirrhosis and primary sclerosing cholangitis are well recognized chronic cholestatic liver diseases that are considered to have an autoimmune basis. Recent progress in the study of autoimmune liver diseases has improved the recognition and characterization of these conditions. An important component of this progress has been the identification of liver disease-associated autoantibodies and their respective target antigens, and the development of specific assays for these autoantibodies. In addition, some nonhumoral immunological findings imply an involvement of specific immunopathogenic mechanisms in the development of these conditions. Furthermore, immunogenetic factors associated with increased susceptibility to some of these diseases have been identified. This article reviews the most relevant information relating to the postulated autoimmune pathogenesis of these diseases, with special emphasis on their associated humoral and cellular immunological abnormalities and immunopathogenetic factors. Some of the remaining important unresolved issues relating to the pathogenesis of these diseases, that need to be addressed in further research, are highlighted.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

Several cholestatic autoimmune liver diseases (AILDs) are recognised. Of these, primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the best characterized. Certain overlap syndromes that are more difficult to characterize, such as the overlap syndrome primary biliary cirrhosis/autoimmune hepatitis and the overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis, can also be classified as cholestatic AILDs.

A number of factors have been considered as possible triggers for the chronicity of the disease process in AILDs, e.g. viruses, bacteria, chemicals, drugs, genes [1]. It is most likely that the manifestations of AILDs arise as a consequence of multiple factors. In most of these diseases, autoantibodies have been identified, their molecular targets characterized and their epitopes mapped. Although these findings are important, the pathogenetic mechanisms that trigger the onset of these diseases, and the precise role of the characteristic autoantibodies associated with them remain unknown. Several risk factors for certain AILDs have been determined, such as immunogenetic background, sex and geographical region. This information needs to be extended and integrated with other relevant complementary information to facilitate the diagnosis and management of cholestatic AILDs. The aim of this article is to review currently available information relating to the etiology, serology, immunogenetics and pathogenesis of PBC and PSC, and to comment briefly on the possibly related cholestatic overlap syndromes.

Primary biliary cirrhosis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

PBC, more accurately termed chronic nonsuppurative destructive cholangitis, is a disease characterized by chronic patchy destruction and obliteration of septal and intrahepatic bile ductules, associated with an infiltration of plasma cells and lymphocytes in the portal tracts, interface hepatitis, fibrosis, and slowly progressive intrahepatic cholestasis. Progression occurs over years or decades. The end stage is an established biliary cirrhosis [2,3].

Unexplained pruritus in a middle-aged subject (particularly a woman) with an elevated serum alkaline phosphatase (two- to five-fold) and/or an elevated serum 5-nucleotidase, suggest PBC. Patients may also present with no symptoms as a consequence of the incidental finding of biochemical index of cholestasis, such as an elevated serum levels of alkaline phosphatase, bile acids or cholesterol. Very rarely, patients present with clinical cholestasis. However, the most specific and sensitive marker of the disease is the presence of a circulating IgG antimitochondrial antibody (AMA), which is detectable in more than 90% of patients (titer > 1 : 40) and is only rarely present in other forms of liver disease [4]. AMA autoantibodies can be found not only in serum but also in the bile [5] and in the saliva of PBC patients [6]. A liver biopsy showing compatible histology is also necessary to make a confident diagnosis of PBC. Interestingly, neither the titer nor the tissue-binding pattern of AMA correlate with clinical disease [7]. In addition to AMA, elevated serum levels of IgM and cryoproteins consisting of immune complex-like structures (not necessarily containing antigen) capable of activating the alternative complement pathway are found in 80–90% of patients [8].

Hyperbilirubinemia is usually only present when the disease has progressed to advanced stages and indicates a poor prognosis [9]. Histologically, biliary epithelial cell damage, accompanied by a T cell rich mononuclear cell portal infiltrate and upregulation of various adhesion molecules (ICAM-1, VCAM-1, LFA, VLA, ELAM-1) on endothelial cells, epithelial cells and inflammatory cells in the portal tracts and hepatic parenchyma are found [10–12]. In the peripheral blood of PBC patients, reduced numbers of T cells may occur due to a selective intrahepatic sequestration of CD8 + T lymphocytes [13]. In addition, impaired activation of CD4 + T cells has been reported in PBC [14].

The AMA autoantibodies recognize inner mitochondrial membrane proteins identified as: the E2 subunits of the pyruvate dehydrogenase complex (PDC-E2); the branched chain 2-oxo acid dehydrogenase complex (BCOADC-E2); the 2-oxoglutarate dehydrogenase complex (OGDC-E2); the E1a and the E1b subunits of PDC (PDC E1a and PDC E1b); and the dihydrolipoamide dehydrogenase-binding protein of the PDC (PDC-E3 BP) or protein X [15–23]. The immunodominant epitopes of PDC-E2 (the major autoantigen found in 90% of PBC patients), BCOADC-E2, OGDC-E2 and PDC-E3BP have been mapped within the lipoic acid binding domains. In contrast to spontaneous autoantibodies found in normal non-PBC sera [24], binding of autoantibodies in PBC sera to these epitopes results in inhibition of the enzymatic activity of PDC, BCOADC-E2 and OGDC-E2, respectively [25–27]. Studies using monoclonal antibodies to these autoantigens have shown a unique staining pattern in the apical region of biliary epithelial cells of PBC patients [28].

Other autoantibodies occur less frequently: a subset of patients with PBC was found to have autoantibodies directed against nuclear envelope proteins. The major autoantigens are the glycoprotein gp210, a transmembrane protein of the nuclear pore complex, whose predominant epitope is a 15 aminoacid sequence in the cytoplasmic, carboxyl-terminal domain of the protein, and p62, a nuclear pore glycoprotein [29,30]. Some patients have autoantibodies against the proteins Sp100 and PML present in nuclear dots [31]. Other less specific autoantibodies in PBC are those against lamin B receptors, a transmembrane protein of the inner nuclear membrane. The mechanism of the organ-specific breakdown of B cell and T cell self-tolerance to these ubiquitous antigens remains uncertain.

AMA autoantibodies may play a pathogenic role in PBC [32]. This requires extracellular (cell surface) expression of the relevant autoantigen (PDC-E2) on biliary epithelial cell surface membranes [33,34] of PBC patients. Regional lymph nodes have also been shown to express increased amounts of both E2 and X protein [35]. The possibility that the antigen is released after tissue damage seems to be unlikely, as AMA autoantibodies are the first abnormality detected early in the course of the disease (before elevation of serum alkaline phosphatase occurs) and they continue to be detectable after liver transplantation for PBC in the presence of normal allograft histology [32,33]. Another possibility would be that autoantibodies might interfere with cellular function as a consequence of penetrating cells, either by endocytosis following binding to brush border myosin or by internalization of IgA AMA through the polymeric immunoglobulin receptor on the basal surface of the biliary epithelial cell [36]. Finally, it has been suggested that a biliary epithelial cell membrane protein, sharing a cross-reactive epitope with PDC-E2, could act as a neoantigen [37 ]. However, the validity of these hypotheses remains to be confirmed. In addition, although biliary epithelial cells express HLA class I and II molecules [34], it seems unlikely that these molecules can present antigen to naive ymphocytes [38].

The possibility that T cells also play a role in the pathogenesis of PBC is suggested by the evidence that autoreactive T cells infiltrate the liver, as shown by immunohistochemical staining of biopsies. Characterization of this tissue infiltrate has been performed, showing that it contains a marked enrichment in CD8 + cytotoxic T cells as compared with peripheral blood ( 39). Recently, it has been shown through immunohistochemical techniques that intrahepatic CD30 + lymphocytes have a role in the IgA type B cell hyperactivity that contributes to the portal tract and bile duct lesions in PBC [40]. The T cell epitope of PDC-E2 in PBC has been studied using T cell lines derived from the peripheral blood mononuclear cells of PBC patients. In a study by Shimoda et al. [41], the minimal epitopes of such T cell clones mapped to the aminoacid sequence 163–176, within the inner lipoyl domain of PDC-E2. This finding suggests an overlap in the PDC-E2 specificity of the T and B cell epitopes in PBC [42–45]. The pattern of lymphokine production of T cell clones derived from PBC patients undergoing liver transplantation indicates that both Th1 and Th2 lymphocytes are involved in the tissue damage that occurs in this disease.

Although the information available on the mechanisms of T cell autoreactivity in PBC is limited, results from investigations using animal models have contributed appreciably to our understanding of this process. In an elegant series of experiments using a murine experimental model of autoimmune liver disease, it has been shown that the breakdown of self-tolerance to PDC-E2 (particularly at the T cell level) represents at least one of the factors that could trigger the development of PBC. In this model, sensitisation of animals to PDC-E2 of mammalian origin resulted in a breakdown of both B cell and T cell tolerance to murine PDC-E2, as well as the development of a nonsuppurative destructive cholangitis [46,47].

The precise mechanisms by which T cells selectively infiltrate the portal tract and damage bile ducts are not clear. It has been shown that in the livers of PBC patients there is increased fibronectin expression on the biliary basement membrane. Integrin alpha4–fibronectin interaction may facilitate adhesion and the penetration of infiltrating alpha4-expressing lymphocytes into the biliary epithelial layer [48]. This phenomenon might be an important step in the pathogenesis of the disease.

Destruction of bile ducts has been shown to involve local apoptotic cell death, a process which is mediated by apoptosis-regulating bcl-2 familial proteins [49]. In this context, not only T cells seem to be involved in the pathogenesis of PBC, but Fas ligand expressing CD68 + monocytes have also been shown to play a role in the apoptotic biliary epithelial cell loss that takes place in this disease [50].

The factors that trigger the development of PBC are unknown. Viral and bacterial infectious agents, as well as certain drugs, have been identified in association with the disease. A high incidence of retroviral antibodies has been reported in patients with PBC, as well as a strong association between the presence of antibodies to double stranded DNA and antibody reactivity to a specific retroviral agent, human intracisternal A-type particle (HIAP). These findings indicate a possible autoimmune response to antigenically-related cellular proteins [51,52]. In addition, in patients with PBC, virus-like particles have been observed by electron microscopy in biliary epithelium, endogenous retroviral sequences have been cloned from liver samples, and antibody reactivity to HIAP has been detected. However, there is no definitive direct evidence to link the endogenous retroviral sequences in PBC patients to the retroviral antibody reactivity or virus like-particles.

Molecular mimicry between bacterial antigens and PDC-E2 has been proposed as a potential mechanism of autoimmunity in PBC [27,41]. However, there is no clear evidence that chronic bacterial infectious processes play a causative role in PBC [53].

Family studies suggest that genetic factors may play a role in determining susceptibility to PBC, and several polymorphic genes may encode factors predisposing to the disease. There is evidence from several different populations to support a role for the major histocompatibility complex (MHC) class II antigen, HLA DR8, in increasing the risk of PBC [54], but other authors have reported associations of PBC with HLA DR3 and possibly HLA DR4 [55] in Caucasians, while in Japanese subjects an association with HLA-DR2 has been reported [56]. The diverse results of these studies may be attributable to differences in the sensitivity of assays and methodology used in analyses, the diversity of ethnic groups studied, as well as possible errors in diagnosis.

Tumour necrosis factor (TNF) polymorphism may also be important. Production of this pro-inflammatory cytokine by lymphocytes of PBC patients is down-regulated. An association has been found between reduced carriage of the rare allele TNF*2 and PBC [57]. In addition, the high frequency of -308 TNF1/TNF1 genotype seen in patients with advanced PBC indicates that this allele may be linked to disease progression. Furthermore, the CTLA-4 exon 1 polymorphism has been identified as the first non-major histocompatibility complex gene conferring susceptibility to develop PBC [58]. Finally, some drugs (e.g. chlorpromazine, nonsteroidal anti-inflammatory drugs) may precipitate a PBC-like cholestatic syndrome [5].

Therapy of PBC patients with ursodeoxycholic acid (UDCA) seems to slow progression of the disease and to reduce AMA titer [59,60], but does not obviate the need for liver transplantation. There seems to be a rationale for immunosuppression, but the commonly used immunosuppressive drugs, including prednisolone, have unacceptable safety profiles, particularly for asymptomatic patients [61].

Primary sclerosing cholangitis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

PSC is a cholestatic syndrome of unknown etiology with a chronic variable course. It is a slowly progressive hepatobiliary disease, characterized by patchy fibro-obliterative inflammation of intrahepatic and extrahepatic bile ducts [62]. The syndrome occurs most frequently in young males and is characterized by: chronic cholestasis; frequent association (50%) with chronic autoimmune inflammatory bowel disease, usually ulcerative colitis; presence of perinuclear antineutrophil cytoplasmic antibodies (p-ANCA); and characteristic cholangiographic abnormalities. The disease usually progresses slowly over a decade, or longer, from an asymptomatic stage to clinical cholestasis and eventually an established biliary cirrhosis. Cholangiocarcinoma is a common late complication [63]. The diagnosis is usually based on the characteristic cholangiographic changes (beading and strictures of bile ducts) and/or compatible hepatic histology (onion skin-like concentric fibrosis around small bile ducts) in a patient with serum biochemical features of mild cholestasis and, possibly, an associated chronic autoimmune inflammatory bowel disease [62].

Several possible etiological factors have been proposed, including infectious (bacteria, viruses), toxic, genetic and immunologic factors [62]. Given that many PSC patients have concomitant ulcerative colitis, the possibility that portal bacteremia or an enterohepatic circulation of toxins exist has been considered by several investigators ( 64,65). Among the infectious factors, the presence of Helicobacter species in the liver in PSC, as well as antibodies to this microorganism in serum of PSC patients have been found with a high frequency [66–68]. However, portal vein bacteremia is rare in PSC patients, as well as among patients undergoing surgery for ulcerative colitis. Therefore, there is little evidence supporting the hypothesis that portal bacteremia may be involved in the etiology of PSC [69]. There are isolated reports of associations between reovirus 3 and cytomegalovirus and PSC [70–72], but no histological features of cytomegalovirus infection have ever been demonstrated in bile duct epithelial cells or hepatocytes of PSC patients [69]. Therefore, there is no convincing evidence that supports the hypothesis that PSC is linked to a viral infection.

Only a genetic predisposition has been shown to be strongly associated with the occurrence of this disease: the HLA haplotypes A1-B8-DRB3*0101-DRB1*0301-DQA1*0501-DQB1*0201 and DRB3*0101-DRB1*1301-DQA1*0103-DQB1* 0603 tend to be associated with PSC. This genetic susceptibility may be determined by polymorphism within the HLA class III region; in particular, a study conducted by Bernal and colleagues [73], showed an association with the TNF2 allele (-238 gene polymorphism) but not with other TNF alleles. TNF2 was significantly increased in the presence of B8 and DRB3*0101 only, and was independent of DRB1*0301. The associations with B8 and TNF2 were stronger than the associations with any of the other HLA class II alleles examined [73].

It has been proposed that both cellular and humoral immune mechanisms may be important in the pathogenesis of PSC. This hypothesis is supported by the occurrence of autoantibodies with several different specificities in PSC, as well as by altered cell mediated immunity in PSC patients. The most prominent autoantibodies in PSC are p-ANCA [74], which comprise a range of autoantibodies with different antigenic specificities including proteinase 3, myeloperoxidase, elastase, bactericidal/permeability-increasing protein, cathepsin G and lactoferrin [75]. An interesting study by Terjung and colleagues [76] has also demonstrated that p-ANCA are antinuclear antibodies reactive with granulocyte-specific antigens present in the nuclear lamina (lamins A, C and B1, and lamin B receptor). Very recently, catalase and alpha-enolase have also been characterized as autoantigens in patients with PSC [77]. Because catalase is an important antioxidant enzyme that prevents cell damage induced by highly reactive oxygen-derived free radicals, an impairment of the redox status of cells by catalase autoantibodies has been suggested as a possible pathogenic mechanism in PSC. A relationship has been established between the abundance of p-ANCA and particular clinical features of PSC [75]. For instance, anticardiolipin antibodies correlate with the Mayo risk score and histologic stage of the disease, i.e. indices of the severity of the disease process [78]; thus, anticardiolipin antibodies might be a prognostic marker in PSC.

Cell mediated immune abnormalities in PSC include a decline in total number of circulating T cells, an increase in the ratio CD4 to CD8 cells and an increase in the number of B cells [79]. There is some evidence to suggest that gamma delta T lymphocytes may be involved in immune-mediated tissue damage in PSC [80]. Finally, it has been postulated that biliary epithelium, by expressing HLA class II antigens, may be able to present autoantigens to T cells [81,82], which may subsequently mediate tissue damage of PCS. For example, B7-2 expression on biliary epithelial cells has recently been shown to be increased in PSC [83]. B7-2 is a costimulatory factor that binds to CD28 on T cells involved in antigen presentation. However, these findings have not been confirmed in an independent study [84], which found no evidence of an antigen-presenting role for the biliary epithelium. Further studies are needed to clarify the role of T cells in tissue damage in PSC.

At present no medical treatment has been shown to slow disease progression in PSC. However, immunosuppressive therapy, as well as UDCA, have been reported to have some efficacy in small uncontrolled studies [62]. In addition, endoscopy with stenting is usually useful in the management of symptomatic dominant strictures involving large extrahepatic bile ducts. Liver transplantation is indicated for end stage disease.

Autoimmune cholangitis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

Autoimmune cholangitis (AIC) is diagnosed in AMA-negative, ANA-positive individuals who have clinical and laboratory features of cholestasis [85–87]. Serum alkaline phosphatase is invariably elevated, and the serum transaminase and gamma-glutamyl transpeptidase levels are also usually increased. AIC is not considered to be an overlap syndrome of PBC and autoimmune hepatitis (AIH). Making a definitive diagnosis may be difficult [88].

Some authors consider that PBC and AIC are components of the same disease spectrum, and they claim that AMA negativity is attributable in part to technical problems with the assay method [32,89]. However, other authors have proposed that antibodies to carbonic anhydrase in AIC are a marker that enables AIC to be differentiated from PBC [90], whereas the antinuclear antibodies anti-Sp100 and anti-Gp210 have been shown to be markers of PBC in patients with features of AIC [91]. Because antilactoferrin antibodies have been found in a large proportion of AIC patients [92], lactoferrin located in bile ducts and liver cells has been proposed as a candidate target antigen in AIC.

Usually, treatment with ursodeoxycholic acid is recommended, and prednisolone therapy is considered; however, results of treatment are uncertain, as no controlled data on therapy have been published.

Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

The overlap syndrome of PBC and AIH is an autoimmune liver disease characterized by the presence of biochemical, serological and histological features typical of both PBC and AIH. Other names for this syndrome are autoimmune cholangiopathy [93], mixed-type chronic aggressive hepatitis and PBC [94], and PBC, hepatitic form [95]. Patients usually have florid piecemeal necrosis and high serum transaminase levels. The syndrome can be differentiated from AIC by the absence in PBC/AIH of histological changes of chronic nonsuppurative cholangitis and the presence of AMA autoantibodies [85]. No specific AMA seems to be associated with this syndrome [96]. Initially, this overlap syndrome was considered to be rare [97], but its prevalence has probably been underestimated [98].

Recent studies have suggested that a PBC-like process precedes the development of this syndrome, because patients at initial presentation have been found to have bile duct lesions histologically or anti-M2 positive AMA autoantibodies [95]. Genetic susceptibility (mainly AIH-associated HLA type 8, DR3 or DR4) may be the reason for progression to a syndrome with many or all of the features of AIH. Combined treatment with immunosuppressive therapy and UDCA is usually recommended, although appropriate controlled therapeutic trials have not been reported.

Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

The overlap syndrome of PSC and AIH was initially described in pediatric patients who fulfilled criteria for the diagnosis of both PSC and AIH [99]. These patients showed typical bile duct strictures and dilatations on endoscopic retrograde cholangiography and typical histological features of chronic hepatitis (interface hepatitis). High titer ANA autoantibodies are present, together with elevated levels of aminotransferases, alkaline phosphatase, gamma-glutamyltranspeptidase and IgG, as well as AMA, and pANCA autoantibodies. Only a few cases have been reported [100–102]. The patients appear to benefit from immunosuppressive treatment.

Open questions

  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References

Although our knowledge of the pathogenesis of cholestatic autoimmune liver diseases has increased substantially during recent years, there are still many questions that remain to be answered. In particular, the precise mechanisms that result in the expression of neoantigens (or loss of self tolerance), and that trigger a local autoimmune reaction against bile duct epithelial cells need to be determined. It is not known with certainty to what extent such phenomena are related to immunogenetic factors. Application of new technologies to the study of these diseases should help to identify risk groups, to improve their classification and, possibly, to determine factors that trigger their development and perpetuate the disease processes. Progress in the field of AILDs should be greatly facilitated by an increased understanding of the fundamental nature of autoimmunity.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Primary biliary cirrhosis
  5. Primary sclerosing cholangitis
  6. Autoimmune cholangitis
  7. Overlap syndrome primary biliary cirrhosis/autoimmune hepatitis
  8. Overlap syndrome primary sclerosing cholangitis/autoimmune hepatitis
  9. Open questions
  10. References
  • 1
    Moreno-Otero R, Garcia-Monzon C, Garcia-Buey L. Pathogenesis of autoimmune liver diseases. In: ArroyoV, BoschJ, BrugueraM, (Eds) Pathogenesis of Autoimmune Liver Diseases. Barcelona: Masson S. A.;1997:p.219 29.
  • 2
    Kaplan MM. Primary biliary cirrhosis. Adv Intern Med 1987;32:359 77.
  • 3
    Moreno-Otero R, Lisker-Melman M, Jones EA. Primary biliary cirrhosis. Med Clin N Am 1989;73:911 29.
  • 4
    Metcalf JV, Mitchison HC, Palmer J, Jones DE, Bassendine ME, James O. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399 402.DOI: 10.1016/s0140-6736(96)04410-8
  • 5
    Nishio A, Van de Water J, Leung PS, Joplin R, Neuberger JM, Lake J et al. Comparative studies of antimitochondrial autoantibodies in sera and bile in primary biliary cirrhosis. Hepatology 1997;25:1085 9.
  • 6
    Reynoso-Paz S, Leung PS, Van De Water J, Tanaka A, Munoz S, Bass N et al. Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis. Hepatology 2000;31:24 9.
  • 7
    Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PS et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997;25:6 11.
  • 8
    Lindgren S & Eriksson S. IgM in primary biliary cirrhosis: Physicochemical and complement activating properties. J Lab Clin Med 1982;99:636 45.
  • 9
    Heathcote J. The clinical expression of primary biliary cirrhosis. Semin Liver Dis 1997;17:23 33.
  • 10
    Nakanuma Y, Yasoshima M, Tsuneyama K, Harada K. Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Semin Liver Dis 1997;17:35 47.
  • 11
    Jones DE. T-cell autoimmunity in primary biliary cirrhosis. Clin Sci (Colch) 1996;91:551 8.
  • 12
    Garcia-Buey L, Garcia-Monzon C, Santander C, Majano PL, Garcia-Sanchez A, Moreno-Otero R. Intrahepatic expression of adhesion and antigen recognition molecules in primary biliary cirrhosis. Hepatology 1994;20:148A.
  • 13
    Moreno-Otero R, Civeira MP, Suou T, Kanof ME, James SP, Jones EA. Reduced numbers of CD8+ T cells and B-cell expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepato-Gastroenterol 1994;41:239 43.
  • 14
    Moreno-Otero R, Murakawa Y, Kanof ME, Civeira MP, Jones EA, James SP. Defective proliferation and regulatory function of CD4+ T cells bearing Leu-8 homing receptor in primary biliary cirrhosis: phorbol myristate acetate enhances T-cell function. Dig Dis Sci 1994;39:1329 36.
  • 15
    Gershwin ME, Coppel RL, Mackay IR. Primary biliary cirrhosis and mitochondrial autoantigens – insights from molecular biology. Hepatology 1988;8:147 51.
  • 16
    Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988;1:1067 70.
  • 17
    Van de Water J, Fregeau D, Davis P, Ansari A, Danner D, Leung P et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988;141:2321 4.
  • 18
    Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988;85:8654 8.
  • 19
    Fregeau DR, Davis PA, Danner DJ, Ansari A, Coppel RL, Dickson ER et al. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol 1989;142:3815 20.
  • 20
    Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME. Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990;144:1671 6.
  • 21
    Surh CD, Roche TE, Danner DJ, Ansari A, Coppel RL, Prindiville T et al. Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex. Hepatology 1989;10:127 33.
  • 22
    Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997;17:49 60.
  • 23
    Dubel L, Tanaka A, Leung PS, Van de Water J, Coppel R, Roche T et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3 bp) and the glycine cleavage proteins in primary biliary cirrhosis . Hepatology 1999;29:1013 8.
  • 24
    Chen QY, Mackay IR, Fida S, Myers MA, Rowley MJ. Natural and disease associated autoantibodies to the autoantigen, dihydrolipoamide acetyltransferase, recognize different epitopes. J Autoimmun 1998;11:151 61.DOI: 10.1006/jaut.1998.0188
  • 25
    Surh CD, Coppel R, Gershwin ME. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol 1990;144:3367 74.
  • 26
    Leung PS, Chuang DT, Wynn RM, Cha S, Danner DJ, Ansari A et al. Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope. Hepatology 1995;22:505 13.
  • 27
    Moteki S, Leung PS, Dickson ER, Van Thiel DH, Galperin C, Buch T et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 1996;23:436 44.
  • 28
    Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998;161:5157 63.
  • 29
    Courvalin JC & Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:79 90.
  • 30
    Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996;110:840 7.
  • 31
    Szostecki C, Guldner HH, Will H. Autoantibodies against ‘nuclear dots’ in primary biliary cirrhosis. Semin Liver Dis 1997;17:71 8.
  • 32
    Neuberger J & Thomson R. PBC and AMA – what is the connection? Hepatology 1999;29:271 6.
  • 33
    Leung PS, Van de Water J, Coppel RL, Nakanuma Y, Munoz S, Gershwin ME. Molecular aspects and the pathological basis of primary biliary cirrhosis. J Autoimmun 1996;9:119 28.DOI: 10.1006/jaut.1996.0015
  • 34
    Tsuneyama K, Van de Water J, Leung PS, Cha S, Nakanuma Y, Kaplan M et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995;21:1031 7.
  • 35
    Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998;352:1595 6.DOI: 10.1016/s0140-6736(98)00064-6
  • 36
    Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997;100:25 31.
  • 37
    Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653 64.
  • 38
    Leon MP, Bassendine MF, Wilson JL, Ali S, Thick M, Kirby JA. Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology 1996;24:561 7.
  • 39
    Meuer SC, Moebius U, Manns MM, Dienes HP, Ramadori G, Hess G et al. Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis. Eur J Immunol 1988;18:1447 52.
  • 40
    Harada K, Tsuneyama K, Hiramatsu K, Nakanuma Y. Significance of CD30-positive lymphocytes in livers in primary biliary cirrhosis. J Gastroenterol Hepatol 1999;14:1197 202.
  • 41
    Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gerschwin ME et al. Mimicry peptides of human PDC-E2, 163–176 peptide, the immunodominant T–cell epitope of primary biliary cirrhosis. Hepatology 2000;31 :1212–6.
  • 42
    Van der Water J, Ansari AA, Surh CD, Coppel R, Roche T, Bonkovsky H et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991;146:89 94.
  • 43
    Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998;102:1831 40.
  • 44
    Van de Water J, Ansari A, Prindiville T, Coppel RL, Ricalton N, Kotzin BL et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med 1995;181:723 33.
  • 45
    Gerschwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210 25.
  • 46
    Jones DEJ, Palmer JM, Yeaman SJ, Kirby JA, Bassendine MF. Breakdown of tolerance to pyruvate dehydrogenase complex in experimental autoimmune cholangitis – a murine model of primary biliary cirrhosis. Hepatology 1999;30:65 70.
  • 47
    Yeaman SJ, Kirby JA, Jones DE. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. Immunol Rev 2000;174:238 49.
  • 48
    Yasoshima M, Tsuneyama K, Harada K, Sasaki M, Gershwin ME, Nakanuma Y. Immunohistochemical analysis of cell-matrix adhesion molecules and their ligands in the portal tracts of primary biliary cirrhosis. J Pathol 2000;190:93 9.DOI: 10.1002/(sici)1096-9896(200001)190:1<93::aid-path507>;2-a
  • 49
    Iwata M, Harada K, Kono N, Kaneko S, Kobayashi K, Nakanuma Y. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis. Hum Pathol 2000;31:179 84.
  • 50
    Iwata M, Harada K, Hiramatsu K, Tsuneyama K, Kaneko S, Kobayashi K et al. Fas ligand expressing mononuclear cells around intrahepatic bile ducts co-express CD68 in primary biliary cirrhosis. Liver 2000;20:129 35.
  • 51
    Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998;351:1620 4.DOI: 10.1016/s0140-6736(97)10290-2
  • 52
    Mason AL, Xu L, Guo L, Garry RF. Retroviruses in autoimmune liver disease: genetic or environmental agents? Arch Immunol Ther Exp 1999;47:289 97.
  • 53
    Tanaka A, Prindiville TP, Gish R, Solnick JV, Coppel RL, Keeffe EB et al. Are infectious agents involved in primary biliary cirrhosis? A PCR Approach. J Hepatol 1999;31:664 71.
  • 54
    Agarwal K, Jones DE, Bassendine MF. Genetic susceptibility to primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:603 6.
  • 55
    Johnston DE, Kaplan MM, Miller KB, Connors CM, Milford EL. Histocompatibility antigens in primary biliary cirrhosis. Am J Gastroenterol 1987;82:1127 9.
  • 56
    Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994;20:225 39.
  • 57
    Gordon MA, Oppenheim E, Camp NJ, Di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999;31:242 7.
  • 58
    Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538 41.
  • 59
    Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342 7.
  • 60
    Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005 13.
  • 61
    Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO. James of. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992;15:336 44.
  • 62
    Ponsioen CI & Tytgat GN. Primary sclerosing cholangitis: a clinical review. Am J Gastroenterol 1998;93:515 23.
    Direct Link:
  • 63
    Rosen CB, Nagorney DM, Wiesner RH, Coffey Rj Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21 5.
  • 64
    Lee YM & Kaplan MM. Primary sclerosing cholangitis. New Engl J Med 1995;332:924 33.
  • 65
    Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989;10:430 6.
  • 66
    Nilsson HO, Castedal M, Olsson R, Wadstrom T. Detection of Helicobacter in the liver of patients with chronic cholestatic liver diseases. J Physiol Pharmacol 1999;50:875 82.
  • 67
    Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol 2000;38:1072 6.
  • 68
    Nilsson I, Lindgren S, Eriksson S, Wadstrom T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut 2000;46:410 4.
  • 69
    Narayanan Menon KV & Wiesner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999;6:343 51.
  • 70
    Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987;5:8 13.
  • 71
    Cello JP. Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease. Am J Med 1989;86:539 46.
  • 72
    Lautenschlager I, Hockerstedt K, Jalanko H, Loginov R, Salmela K, Taskinen E et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997;25:190 4.
  • 73
    Bernal W, Moloney M, Underhill J, Donaldson PT. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol 1999;30:237 41.
  • 74
    Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, IgG subclass. Gut 1996;38:387 9.
  • 75
    Roozendaal C, Van Milligen de Wit AW, Haagsma EB, Horst G, Schwarze C, Peter HH et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998;105:393 9.DOI: 10.1016/s0002-9343(98)00294-0
  • 76
    Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998;28:332 40.
  • 77
    Orth T, Kellner R, Diekmann O, Faust J, Meyer zum Buschenfelde KH, Mayet WJ. Identification anc characterisation of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998;112:507 15.DOI: 10.1046/j.1365-2249.1998.00583.x
  • 78
    Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182 7.
  • 79
    Snook JA, Chapman RW, Sachdev GK, Heryet A, Kelly PM, Fleming KA et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989;9:36 41.
  • 80
    Martins EB, Graham AK, Chapman RW, Fleming KA. Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases. Hepatology 1996;23:988 93.
  • 81
    Broome U, Glaumann H, Hultcrantz R, Forsum U. Distribution of HLA-DR, HLA-DP.HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990;25:54 8.
  • 82
    Chapman RW, Kelly PM, Heryet A, Jewell DP, Fleming KA. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988;29:422 7.
  • 83
    Tsuneyama K, Harada K, Yasoshima M, Kaji K, Gershwin ME, Nakanuma Y. Expression of co-stimulatory factor B7–2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis: an immunohistochemical study. J Pathol 1998;186:126 30.DOI: 10.1002/(sici)1096-9896(1998100)186:2<126::aid-path167>;2-1
  • 84
    Ponsioen CY, Kuiper H, Ten Kate FJ, Van Milligen de Wit M, Van Deventer SJ, Tytgat GN. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1999;11:769 74.
  • 85
    Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994;35:260 5.
  • 86
    Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994;18:91 9.
  • 87
    Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232 42.
  • 88
    Kinoshita H, Omagari K, Whittingham S, Kato Y, Ishibashi H, Sugi K et al. Autoimmune cholangitis and primary biliary cirrhosis – an autoimmune enigma. Liver 1999;19:122 8.
  • 89
    Nakajima M, Shimizu H, Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J Gastroenterol 1999;34:607 12.DOI: 10.1007/s005350050380
  • 90
    Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995;108:1802 9.
  • 91
    Romero Gomez M, Wichmann I, Otero Fernandez MA, Suarez Garcia E, Grande L, Nunez J Et Al. Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis. Gastroenterol Hepatol 1999;22:11 3.
  • 92
    Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol 1998;93:1334 9.
    Direct Link:
  • 93
    Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10 5.
  • 94
    Kloppel G, Seifert G, Lindner H, Dammermann R, Sack HJ, Berg PA. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat 1977;373:143 60.
  • 95
    Lohse AW, Zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterisation of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078 84.
  • 96
    Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 1992;16:1128 36.
  • 97
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360 5.
  • 98
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296 301.
  • 99
    Mieli-Vergani G, Lobo-Yeo A, McFarlane BM, McFarlane IG, Mowat AP, Vergani D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology 1989;9:198 203.
  • 100
    McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93:777 84.
    Direct Link:
  • 101
    Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699 705.
  • 102
    Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369 76.